WilmerHale represented the underwriters in the follow-on public offering of 9,627,640 shares of common stock and 28,084 shares of Series B non-voting convertible preferred stock (“Series B Preferred Stock”) of Viridian Therapeutics, Inc., a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies. The shares of common stock were issued at a public offering price of $23.50 per share.  The Series B Preferred Stock had a public offering price of $1,566.745 per share. The gross proceeds to Viridian were $254 million, before deducting underwriting discounts, commissions and offering expenses. The offering priced on August 16, 2022 and closed on August 19, 2022.

The WilmerHale team representing the underwriters consisted of Lisa Firenze, Molly Fox, Andrea Sorrentino and Milan Kumar, with assistance from Bruce Manheim and Colleen Superko.